Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Ventilator Associated Pneumonia (VAP) Overview 9 Therapeutics Development 10 Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 10 Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 11 Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 12 Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 13 Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 18 Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 19 Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 20 Achaogen Inc. 20 Adenium Biotech ApS 21 Aridis Pharmaceuticals LLC 22 AstraZeneca Plc 23 Cardeas Pharma Corp. 24 MedImmune, LLC 25 Meiji Seika Pharma Co., Ltd. 26 Merck & Co., Inc. 27 Motif Bio Plc 28 Nabriva Therapeutics AG 29 Savara Inc. 30 Tetraphase Pharmaceuticals Inc. 31 Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 (amikacin + fosfomycin) - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 (avibactam + ceftazidime) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 (ceftolozane sulfate + tazobactam sodium) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (cilastatin sodium + imipenem + relebactam) - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AA-139 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Aerucin - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 arbekacin - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 eravacycline - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 fosfomycin tromethamine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 iclaprim mesylate - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 lefamulin acetate - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 MEDI-4893 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Nu-2 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Panaecin - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 panobacumab - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 plazomicin sulfate - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Qn-2251 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 tedizolid phosphate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 tosatoxumab - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 vancomycin hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Ventilator Associated Pneumonia (VAP) - Recent Pipeline Updates 79 Ventilator Associated Pneumonia (VAP) - Dormant Projects 104 Ventilator Associated Pneumonia (VAP) - Discontinued Products 105 Ventilator Associated Pneumonia (VAP) - Product Development Milestones 106 Featured News & Press Releases 106 Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 106 Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured 106 Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 106 May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 107 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 108 Disclaimer 109

List of Tables Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2016 10 Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Comparative Analysis by Unknown Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc., H1 2016 20 Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H1 2016 21 Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 22 Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H1 2016 23 Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H1 2016 24 Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune, LLC, H1 2016 25 Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 26 Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co., Inc., H1 2016 27 Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H1 2016 28 Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H1 2016 29 Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H1 2016 30 Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Ventilator Associated Pneumonia (VAP) Therapeutics - Recent Pipeline Updates, H1 2016 79 Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2016 104 Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2016 105 List of Figures Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2016 10 Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Top 10 Targets, H1 2016 34 Number of Products by Stage and Top 10 Targets, H1 2016 34 Number of Products by Top 10 Mechanism of Actions, H1 2016 36 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 36 Number of Products by Routes of Administration, H1 2016 38 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 38 Number of Products by Molecule Types, H1 2016 40 Number of Products by Stage and Molecule Types, H1 2016 40

Achaogen Inc. Adenium Biotech ApS Aridis Pharmaceuticals LLC AstraZeneca Plc Cardeas Pharma Corp. MedImmune, LLC Meiji Seika Pharma Co., Ltd. Merck & Co., Inc. Motif Bio Plc Nabriva Therapeutics AG Savara Inc. Tetraphase Pharmaceuticals Inc.